Geriatrics, elderly, toxicity, Chemotherapy, radiotherapy, Immunotherapygeriatría, anciano, Toxicidad aguda, Toxicidad crónica, quimioterapia, radioterapia, InmunoterapiaCâncer, ANCIANO, GERIATRIA, QUIMIOTERAPIA, RADIOTERAPIA, TOXICIDAD AGUDA, TOXICIDAD CRÓNICA

1. Verduzco-Aguirre HC, Navarrete-Reyes AP, Negrete-Najar JP, Soto-Pérez-De-Celis E. Cáncer en el adulto mayor en Latinoamérica: cooperación interdisciplinaria entre oncología y geriatría. Rev Salud Pública. 2020;22(3):1-9. https://doi.org/10.15446/rsap.V22n3.84617
2. Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. https://doi.org/10.3322/caac.21492
3. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021 May;71(3):209-49. https://doi.org/10.3322/caac.21660
4. International Agency for Research on Cancer. Colombia: Globocan 2020 [internet]. 2021 [citado 2021 mar 24]. Disponible en: https://gco.iarc.fr/today/data/factsheets/populations/170-colombia-fact-sheets.pdf
5. Smith BD, Smith GL, Hurria A, Hortobagyi GN, Buchholz TA. Future of cancer incidence in the United States: Burdens upon an aging, changing nation. J Clin Oncol. 2009;27(17):2758-65. https://doi.org/10.1200/JCO.2008.20.8983
6. Hurria A, Dale W, Mooney M, Rowland JH, Ballman KV, Cohen HJ, et al. Designing therapeutic clinical trials for older and frail adults with cancer: U13 conference recommendations. J Clin Oncol. 2014;32(24):2587-94. https://doi.org/10.1200/JCO.2013.55.0418
7. DeSantis CE, Miller KD, Dale W, Mohile SG, Cohen HJ, Leach CR, et al. Cancer statistics for adults aged 85 years and older, 2019. CA Cancer J Clin. 2019 Nov 1;69(6):452-67. https://doi.org/10.3322/caac.21577
8. Feliu J, Heredia-Soto V, Gironés R, Jiménez-Munarriz B, Saldaña J, Guillén-Ponce C, et al. Can we avoid the toxicity of chemotherapy in elderly cancer patients? Crit Rev Oncol Hematol. 2018;131(June):16-23. https://doi.org/10.1016/j.critrevonc.2018.08.008
9. Mohile SG, Dale W, Somerfield MR, Schonberg MA, Boyd CM, Burhenn PS, et al. Practical assessment and management of vulnerabilities in older patients receiving chemotherapy: ASCO guideline for geriatric oncology. J Clin Oncol. 2018;36(22):2326-47. http://10.0.4.176/jco.2018.78.8687
10. Schiefen JK, Madsen LT, Dains JE. Treatment risk in the senior population. J Adv Pract Oncol [internet]. 2017 Jul-Aug;8(5):528-33. Disponible en: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6067916/
11. Beracasa L. Toxicidad relacionada con el tratamiento para el cáncer en adultos mayores. Revisión de la literatura. Univ Med. 2021;62(1). https://doi.org/10.11144/Javeriana.umed62-1.toxi
12. Kotzerke D, Moritz F, Mantovani L, Hambsch P, Hering K, Kuhnt T, et al. The performance of three oncogeriatric screening tools - G8, optimised G8 and CARG - in predicting chemotherapy-related toxicity in older patients with cancer: a prospective clinical study. J Geriatr Oncol. 2019;10(6):937-43.
13. Wang TQ, Samuel JN, Brown MC, Vennettilli A, Solomon H, Eng L, et al. Routine surveillance of chemotherapy toxicities in cancer patients using the Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Oncol Ther. 2018;6(2):189-201. https://doi.org/10.1007/s40487-018-0065-7
14. Cancer Therapy Evaluation Program (CTEP). Common Terminology Criteria for Adverse Events (CTCAE).v.5.0 [5x7]. Cancer Therapy Evaluation Program (CTEP) [internet]. 2017;155. Disponible en: https://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htm#ctc_50
15. Anderson JM. Biocompatibility. En: Polymer science: a comprehensive reference. New York: Elsevier; 2012. p. 363-83.
16. Livshits Z, Rao RB, Smith SW. An approach to chemotherapy-associated toxicity. Emerg Med Clin North Am. 2014;32(1):167-203.
17. Hommes JW, Verheijden RJ, Suijkerbuijk KPM, Hamann D. Biomarkers of checkpoint inhibitor induced immune-related adverse events—a comprehensive review. Front Oncol. 2021;10(February):1-16.
18. Robert C. A decade of immune-checkpoint inhibitors in cancer therapy. Nat Commun. 2020;11(1):10-2. https://doi.org/10.1038/s41467-020-17670-y
19. O’Donovan A, Leech M, Gillham C. Assessment and management of radiotherapy induced toxicity in older patients. J Geriatr Oncol. 2017;8(6):421-7. https://doi.org/10.1016/j.jgo.2017.07.001
20. Keenan LG, O’Brien M, Ryan T, Dunne M, McArdle O. Assessment of older patients with cancer: Edmonton Frail Scale (EFS) as a predictor of adverse outcomes in older patients undergoing radiotherapy. J Geriatr Oncol. 2017;8(3):206-10. https://doi.org/10.1016/j.jgo.2016.12.006
21. Alexandre J, Cautela J, Ederhy S, Damaj GL, Salem JE, Barlesi F, et al. Cardiovascular toxicity related to cancer treatment: a pragmatic approach to the American and European cardio-oncology guidelines. J Am Heart Assoc. 2020;9(18):e018403. https://doi.org/10.1161/JAHA.120.018403
22. Pulito C, Cristaudo A, Porta C La, Zapperi S, Blandino G, Morrone A, et al. Oral mucositis: the hidden side of cancer therapy. J Exp Clin Cancer Res. 2020 Oct 7;39(1):210. https://doi.org/10.1186/s13046-020-01715-7
23. Kusiak A, Alicjajereczek-Fossa B, Cichońska D, Alterio D. Oncological-therapy related oral mucositis as an interdisciplinary problem—literature review. Int J Environ Res Public Health. 2020 Apr 3;17(7):2464. https://doi.org/10.3390/ijerph17072464
24. Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev. 2020 May 13;14(1):442. https://doi.org/10.4081/oncol.2020.442
25. Salzmann M, Marmé F, Hassel JC. Prophylaxis and management of skin toxicities. Breast Care (Basel). 2019 Apr;14(2):72-77. https://doi.org/10.1159/000497232
26. Trüeb RM. Chemotherapy-induced alopecia. Semin Cutan Med Surg. 2009 Mar;28(1):11-4.
27. Pinkerton RC, Ph D, Rogers LM. Sequelae and Alopecia Among. 2001;9(6):283-9. https://doi.org/10.1046/j.1523-5394.2001.96007.x
28. Münstedt K, Manthey N, Sachsse S, Vahrson H. Changes in self-concept and body image during alopecia induced cancer chemotherapy. Support Care Cancer. 1997;5(2):139-43. https://doi.org/10.1007/BF01262572
29. Wang S, Yang T, Shen A, Qiang W, Zhao Z, Zhang F. The scalp cooling therapy for hair loss in breast cancer patients undergoing chemotherapy: a systematic review and meta-analysis. Support Care Cancer. 2021 Nov;29(11):6943-56. https://doi.org/10.1007/s00520-021-06188-8
30. Brown TJ, Gupta A. Management of cancer therapy-associated oral mucositis. J Oncol Pract. 2020;16(3):103-9. https://doi.org/10.1200/JOP.19.00652
31. Villa A, Sonis ST. Pharmacotherapy for the management of cancer regimen-related oral mucositis. Expert Opin Pharmacother. 2016;17(13):1801-7. https://doi.org/10.1080/14656566.2016.1217993
32. Elad S, Cheng KKF, Lalla RV, Yarom N, Hong C, Logan RM, et al. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy. Cancer. 2020;126(19):4423-31. https://doi.org/10.1002/cncr.33100
33. Elting LS, Cooksley C, Chambers M, Cantor SB, Manzullo E, Rubenstein EB. The burdens of cancer therapy. Clinical and economic outcomes of chemotherapy-induced mucositis. Cancer. 2003 Oct;98(7):1531-9. https://doi.org/10.1002/cncr.11671
34. Jones JA, Avritscher EBC, Cooksley CD, Michelet M, Bekele BN, Elting LS. Epidemiology of treatment-associated mucosal injury after treatment with newer regimens for lymphoma, breast, lung, or colorectal cancer. Support Care Cancer. 2006 Jun;14(6):505-15. https://doi.org/10.1007/s00520-006-0055-4
35. Keefe DM, Schubert MM, Elting LS, Sonis ST, Epstein JB, Raber-Durlacher JE, et al. Updated clinical practice guidelines for the prevention and treatment of mucositis. Cancer. 2007 Mar;109(5):820-31. https://doi.org/10.1002/cncr.22484
36. Sonis ST, Elting LS, Keefe D, Peterson DE, Schubert M, Hauer-Jensen M, et al. Perspectives on cancer therapy-induced mucosal injury: pathogenesis, measurement, epidemiology, and consequences for patients. Cancer. 2004 May;100(9 Suppl):1995-2025. https://doi.org/10.1002/cncr.20162
37. Sonis ST. The pathobiology of mucositis. Nat Rev Cancer. 2004 Apr;4(4):277-84.
38. Barasch A, Peterson DE. Risk factors for ulcerative oral mucositis in cancer patients: unanswered questions. Oral Oncol. 2003 Feb;39(2):91-100.
39. Bensadoun RJ. Photobiomodulation or low-level laser therapy in the management of cancer therapy-induced mucositis, dermatitis and lymphedema. Curr Opin Oncol. 2018 Jul;30(4):226-32. https://doi.org/10.1097/CCO.0000000000000452
40. Al-Rudayni AHM, Gopinath D, Maharajan MK, Veettil SK, Menon RK. Efficacy of photobiomodulation in the treatment of cancer chemotherapy-induced oral mucositis: A meta-analysis with trial sequential analysis. Int J Environ Res Public Health. 2021 Jul 12;18(14):7418. https://doi.org/10.3390/ijerph18147418
41. Tamburin S, Park SB, Schenone A, Mantovani E, Hamedani M, Alberti P, et al. Rehabilitation, exercise, and related non-pharmacological interventions for chemotherapy-induced peripheral neurotoxicity: Systematic review and evidence-based recommendations. Crit Rev Oncol Hematol. 2022 Mar;171:103575. https://doi.org/10.1016/j.critrevonc.2021.103575
42. Sarezky J, Sachs G, Elinzano H, Stavros K. Cancer and peripheral nerve disease. Clin Geriatr Med. 2021 May;37(2):289-300. https://doi.org/10.1016/j.cger.2021.01.003
43. Seretny M, Currie GL, Sena ES, Ramnarine S, Grant R, MacLeod MR, et al. Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: A systematic review and meta-analysis. Pain [Internet]. 2014;155(12). Disponible en: https://journals.lww.com/pain/fulltext/2014/12000/incidence,_prevalence,_and_predictors_of.6.aspx
44. Jordan B, Margulies A, Cardoso F, Cavaletti G, Haugnes HS, Jahn P, et al. Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO-EONS-EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up. Ann Oncol. 2020 Oct;31(10):1306-1319. https://doi.org/10.1016/j.annonc.2020.07.003
45. Cavaletti G, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity. Curr Opin Neurol. 2015 Oct;28(5):500-7. https://doi.org/10.1097/WCO.0000000000000234
46. Cavaletti G, Alberti P, Marmiroli P. Chemotherapy-induced peripheral neurotoxicity in cancer survivors: an underdiagnosed clinical entity? Am Soc Clin Oncol Educ Book. 2015:e553-60. https://doi.org/10.14694/EdBook_AM.2015.35.e553
47. Wang AB, Housley SN, Flores AM, Kircher SM, Perreault EJ, Cope TC. A review of movement disorders in chemotherapy-induced neurotoxicity. J Neuroeng Rehabil. 2021 Jan 25;18(1):16. https://doi.org/10.1186/s12984-021-00818-2
48. Arnold B, Mitchell SA, Lent L, Mendoza TR, Rogak LJ, Barragán NM, et al. Linguistic validation of the Spanish version of the National Cancer Institute’s Patient-Reported Outcomes version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE). Support Care Cancer. 2016;24(7):2843-51. https://doi.org/10.1007/s00520-015-3062-5
49. Derman BA, Davis AM. Recommendations for prevention and management of chemotherapy-induced peripheral neuropathy. JAMA. 2021 Sep 21;326(11):1058-9. https://doi.org/10.1001/jama.2021.7458
50. Perazella MA. Onco-nephrology: Renal toxicities of chemotherapeutic agents. Clin J Am Soc Nephrol. 2012 Oct 5;7(10):1713-21.
51. Małyszko J, Kozłowska K, Kozłowski L, Małyszko J. Nephrotoxicity of anticancer treatment. Nephrol Dial Transplant. 2017 Jun 1;32(6):924-936. https://doi.org/10.1093/ndt/gfw338
52. Tuch G, Soo WK, Luo KY, Frearson K, Oh EL, Phillips JL, et al. Cognitive assessment tools recommended in geriatric oncology guidelines: a rapid review. Curr Oncol. 2021 Oct 8;28(5):3987-4003. https://doi.org/10.3390/curroncol28050339
53. Magnuson A, Mohile S, Janelsins M. Cognition and cognitive impairment in older adults with cancer. Curr Geriatr Rep. 2016 Sep;5(3):213-219. https://doi.org/10.1007/s13670-016-0182-9
54. Mayo SJ, Lustberg M, Dhillon HM, Nakamura ZM, Allen DH, Ah D, et al. Cancer-related cognitive impairment in patients with non-central nervous system malignancies: an overview for oncology providers from the MASCC Neurological Complications Study Group. Support Care Cancer. 2021 Jun;29(6):2821-40. https://doi.org/10.1007/s00520-020-05860-9
55. Magnuson A, Ahles T, Chen BT, Mandelblatt J, Janelsins MC. Cognitive function in older adults with cancer: assessment, management, and research opportunities. J Clin Oncol. 2021;39(19):2138-49. https://doi.org/10.1200/JCO.21.00239
56. Edelstein A, Pergolizzi D, Alici Y. Cancer-related cognitive impairment in older adults. Curr Opin Support Palliat Care. 2017 Mar;11(1):60-69. https://doi.org/10.1097/SPC.0000000000000254

Vol. 64 Núm. 4 (2023)